Response to COVID-19 vaccine positive in patients with IBD
(HealthDay)—Inflammatory bowel disease (IBD) patients taking biologics achieved a positive antibody response to both the Moderna and Pfizer COVID-19 vaccines, […]
» Read moreLONDON (Reuters) – A single dose of Pfizer’s coronavirus vaccine may not generate a sufficient immune response to protect against […] The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic emerged in late 2019 in Wuhan, China, and has led to […] New research led by Naresh Trehan of Medanta-The Medicity in India found the COVISHIELD (ChAdOx1 nCoV-19 Corona Virus Vaccine) vaccine […] Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a […] The airport says a lot about Cortez, Colorado: The single-engine planes that fly into its one-room airport seat nine passengers […] Amidst the continued surge of coronavirus disease (COVID-19) cases, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccination […] Johnson & Johnson asked other vaccine makers to join a study of blood clot risks, but Pfizer and Moderna DECLINED […] People who have recovered from COVID-19 had a robust antibody response after the first mRNA vaccine dose, but little immune […] The head of Pfizer said Thursday the company’s COVID vaccine, among the priciest on the market, is no more expensive […]
Risk From Variants Remains After First Pfizer Vaccine: Study
Single dose of J&J's Ad26.COV2.S vaccine effective against SARS-CoV-2 including in South Africa variant
Real-world study in India finds COVISHIELD vaccine safe and effective
Malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal
Snag a Vaccine Appointment, Then Face the Next Hurdle: How to Get There?
Research says benefits of continuing immunization of front-line workers in BC with AstraZeneca vaccine far outweigh risks
J&J asked other vaccine makers to join a study of blood clot risks
Recovered COVID-19 patients may need only a single vaccine dose, suggests study
Pfizer defends high cost of COVID vaccine
